title: Burkholderia cenocepacia phenotypic clonal variation during a 3.5-year colonization in the lungs of a cystic fibrosis patient.
abstract: Chronic lung infection is the major cause of morbidity and premature mortality in cystic fibrosis (CF) patients. Bacteria of the Burkholderia cepacia complex are the most threatening pathogens in CF, and a better understanding of how these bacteria adapt to the CF airway environment and resist the host defense mechanisms and therapeutically administered antibiotics is crucial. To provide clues to the adaptive strategies adopted by Burkholderia cenocepacia during long-term colonization, we carried out a phenotypic assessment of 11 clonal variants obtained at the major Portuguese CF Center in Lisbon from sputa of the same CF patient during 3.5 years of colonization of the lungs, until the patient's death with cepacia syndrome. Phenotypic characterization included susceptibility assays against different classes of antimicrobials and characterization of cell motility, cell hydrophobicity and zeta potential, colony and cell morphology, fatty acid composition, growth under iron limitation/load conditions, exopolysaccharide production, and size of the biofilms formed. The results suggest the occurrence of clonal expansion during long-term colonization. For a number of the characteristics tested, no isolation time-dependent consistent alteration pattern could be identified. However, the values for antimicrobial susceptibility and swarming motility for the first B. cenocepacia isolate, thought to have initiated the infection, were consistently above those for the clonal variants obtained during the course of infection, and the opposite was found for the zeta potential. The adaptive strategy for long-term colonization, described here for the first time, involved the alteration of membrane fatty acid composition, in particular a reduction of the degree of fatty acid saturation, in the B. cenocepacia variants retrieved, along with the deterioration of pulmonary function and severe oxygen limitation.
authors.affiliation: Institute for Biotechnology and Bioengineering, Centre for Biological and Chemical Engineering, Instituto Superior Técnico, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
authors.forename: Carla P
authors.initials: CP
authors.lastname: Coutinho
authors.forename: Carla C C R
authors.initials: CC
authors.lastname: de Carvalho
authors.forename: Andreia
authors.initials: A
authors.lastname: Madeira
authors.forename: Ana
authors.initials: A
authors.lastname: Pinto-de-Oliveira
authors.forename: Isabel
authors.initials: I
authors.lastname: Sá-Correia
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001483:Base Sequence; D019121:Burkholderia Infections / Q000382:microbiology* / Q000503:physiopathology; D057508:Burkholderia cenocepacia / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology; D002462:Cell Membrane / Q000737:chemistry; D003550:Cystic Fibrosis / Q000382:microbiology* / Q000503:physiopathology; D005227:Fatty Acids / Q000032:analysis; D006801:Humans; D008168:Lung / Q000382:microbiology*; D008171:Lung Diseases / Q000382:microbiology; D008563:Membrane Lipids / Q000032:analysis; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010641:Phenotype; D011110:Polymorphism, Genetic
chemical_list: D000900:Anti-Bacterial Agents; D005227:Fatty Acids; D008563:Membrane Lipids